Chemistry Holdings
Innovative product creation & business growth partner to the food, beverage, nutrition & social impact communities.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
N/A | Seed | ||
| Total Funding | 000k | ||
Related Content
Chemistry Holdings, established in 2016 by founder Josh Held, operates as a formulation technology company focused on creating advanced delivery systems for the nutraceutical and pharmaceutical sectors. Held, an entrepreneur with a background spanning finance, law, sales, and marketing, including a tenure as Vice President of Investments at JP Morgan, founded the company to innovate within the wellness space. His vision centers on maximizing the utility and delivery of molecules to enhance product stability and efficacy.
The company's core business involves the development of novel biopolymer technology for both liquid and dry powder encapsulation. This technology is engineered to improve the stability and solubility of active ingredients, offering clients in the food and beverage, wellness, and pharmaceutical industries sustainably made products. Chemistry Holdings functions as a business growth partner, providing support from a team of scientists, market strategists, and product designers to help clients bring new products to market. The company's revenue model appears to be based on contract manufacturing, licensing its technology, and forming strategic partnerships.
A significant milestone in the company's history was its planned acquisition by CURE Pharmaceutical, which was announced in April 2019. This all-stock transaction was intended to merge Chemistry Holdings' formulation technologies—including chewable delivery systems, nanoemulsions, and microcapsules—with CURE's expertise in oral thin films (CUREfilm™). The goal of the merger was to create a more versatile platform capable of delivering a wider range of active ingredients at higher doses. As part of the agreement, Chemistry Holdings was to contribute at least $8 million in cash to the new combined entity, and Josh Held was slated to join CURE's Board of Directors.
Keywords: formulation technology, drug delivery systems, nutraceuticals, pharmaceuticals, biopolymer technology, microencapsulation, liquid encapsulation, active ingredient stability, active ingredient solubility, sustainable materials, wellness products, food and beverage innovation, molecule delivery, contract manufacturing, technology licensing, nanoemulsions, chewable pods, oral thin film, CURE Pharmaceutical, Josh Held